Bionano Genomics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Bionano Genomics Inc.
- Former names
- BioNanomatrix Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 3826 — Laboratory Analytical Instruments
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BNGO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001411690
- EIN
- 26-1756290
Board of directors
-
Albert Luderer · Director · Interim Chief ExecutiveSince 2023
-
Aleksandar Rajkovic · DirectorSince 2023
-
Christopher J. Twomey · DirectorSince 2023
-
David L. Barker · DirectorSince 2023
-
Hannah Mamuszka · DirectorSince 2023
-
Kristiina Vuori M.D. · DirectorSince 2023
-
R. Erik Holmlin · Director · PRESIDENT AND CEOSince 2023
-
Vincent Jung-Fai Wong · DirectorSince 2023
-
Yvonne Linney · DirectorSince 2023
Chief executives
R. Erik Holmlin
· President and CEO
Dates unknown
Dates unknown
Director election results
Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.5%
-
87.5%
Board connections
2 of this board's directors also sit on 2 other boards.
- via Kristiina Vuori M.D.
- via Christopher J. Twomey
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $9,705
- 2 purchases by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 4, 2026 | Albert Luderer Director, Officer (Interim Chief Executive) | Open-market purchase | +4,000 | $1.21 | $4,845 |
| Aug 21, 2026 | Albert Luderer Director, Officer (Interim Chief Executive) | Open-market purchase | +4,000 | $1.22 | $4,860 |
| Jun 3, 2026 | Dixon Jonathan V. Officer (GENERAL COUNSEL) | Shares withheld for tax | −24 | $1.30 | $31 |
| Jun 3, 2026 | OLDAKOWSKI MARK Officer (CHIEF OPERATING OFFICER) | Shares withheld for tax | −27 | $1.30 | $35 |
| Jun 3, 2026 | Chaubey Alka Officer (CHIEF MEDICAL OFFICER) | Shares withheld for tax | −24 | $1.30 | $31 |
| Jun 3, 2026 | Adamchak Mark Officer (Principal Accounting Officer) | Shares withheld for tax | −7 | $1.30 | $9 |
| Feb 17, 2026 | Chaubey Alka Officer (CHIEF MEDICAL OFFICER) | Shares withheld for tax | −18 | $1.10 | $20 |
| Feb 17, 2026 | Adamchak Mark Officer (Principal Accounting Officer) | Shares withheld for tax | −3 | $1.10 | $3 |
| Feb 17, 2026 | Dixon Jonathan V. Officer (GENERAL COUNSEL) | Shares withheld for tax | −6 | $1.10 | $7 |
| Feb 17, 2026 | OLDAKOWSKI MARK Officer (CHIEF OPERATING OFFICER) | Shares withheld for tax | −20 | $1.10 | $22 |
| Feb 17, 2026 | R. Erik Holmlin Director, Officer (PRESIDENT AND CEO) | Shares withheld for tax | −51 | $1.10 | $56 |
| Sep 11, 2025 | OLDAKOWSKI MARK Officer (Chief Operating Officer) | Shares withheld for tax | −59 | $4.06 | $240 |
| Sep 11, 2025 | Chaubey Alka Officer (Chief Medical Officer) | Shares withheld for tax | −51 | $4.06 | $207 |
| Jun 3, 2025 | OLDAKOWSKI MARK Officer (Chief Operating Officer) | Shares withheld for tax | −27 | $3.69 | $100 |
| Jun 3, 2025 | Adamchak Mark Officer (Principal Accounting Officer) | Shares withheld for tax | −7 | $3.69 | $26 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.